Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 16, 2021 12:42pm
106 Views
Post# 33560039

RE:Clinical Supply Manager

RE:Clinical Supply ManagerThe NASH phase III is delayed, at best, and they are hiring a clinical supply manager after a preclinical project manager two weeks ago and they actively advertise that on Linkedin. To me they look very confident that they will have a lot of work on both the clinical and preclinical sides of oncology. The preclinical to work on new PDCs, and the clinical because they think TH1902 will go forward and that with the fasttrack designation they need to be ready, because this thing can really embark on the fast track.


jfm1330 wrote:
 

Job Description

The incumbent will be responsible for establishing and managing all the supply chain related activities for the clinical projects at Theratechnologies Inc. Please note that this position may be based in Dublin, Ireland, or Montreal, Quebec, Canada, depending on the location of the successful candidate.

Required Qualifications

  • Bachelor's degree in science or equivalent
  • 5 years of team management experience
  • 5 years of relevant experience in a supply chain role
  • 5 years of experience in a pharmaceutical or biotechnology company
  • Good knowledge of European guidelines, laws, regulations, and regulatory practices (Good Manufacturing Practices (GMP), Good Distribution Practices (GDP))
  • Excellent communicator, and well-organized with superior presentation skills
  • Understand the quality mechanisms for releasing batches of manufactured drugs.
  • Knowledge of Word, Excel, Power Point, Outlook, and Project



<< Previous
Bullboard Posts
Next >>